Security
Bio-Rad Laboratories, Inc. Class B · BIO B
BIO BNYSECommon stockCurrentCIK 12208Updated Nov 6, 2026
Name history
BIO RAD LABORATORIES INC · through Jun 18, 2018
BIO B price & chart
This symbol dialect needs an exact provider mapping.
About the company
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,100 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com
In the news
No coverage from other publishers is available.
SEC disclosures
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Regulation FD Disclosure
Items 2.02, 2.05, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 9,696,400,000Source | 10,603,472,000Source | 10,252,000,000Source | 10,214,100,000Source | 9,688,446,000Source | 9,790,000,000Source | 9,526,900,000Source | 12,609,893,000Source | 10,576,500,000Source | 9,364,100,000Source | 12,299,070,000Source | 13,501,666,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | 539,900,000Source | 528,100,000Source | 529,007,000Source | 498,612,000Source |
| GoodwillUSD | 578,700,000Source | 415,100,000Source | 574,300,000Source | 581,600,000Source | 412,116,000Source | 577,100,000Source | 414,600,000Source | 412,817,000Source | 579,800,000Source | 410,500,000Source | 413,569,000Source | 406,488,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 388,400,000Source | 307,325,000Source | 160,000,000Source | 396,900,000Source | 307,093,000Source | 166,800,000Source | 296,100,000Source | 313,602,000Source | 174,300,000Source | 293,600,000Source | 320,514,000Source | 332,147,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 395,800,000Source | 410,400,000Source | 517,000,000Source | 369,300,000Source | 406,900,000Source | 507,200,000Source | 521,400,000Source | 433,300,000Source | 529,800,000Source | 488,100,000Source | 403,815,000Source | 434,215,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 464,700,000Source | 461,940,000Source | 441,800,000Source | 469,900,000Source | 445,506,000Source | 426,200,000Source | 424,700,000Source | 444,809,000Source | 460,600,000Source | 452,500,000Source | 489,017,000Source | 494,645,000Source |
| Inventory, NetUSD | 783,200,000Source | 804,276,000Source | 780,600,000Source | 798,800,000Source | 803,693,000Source | 770,500,000Source | 790,100,000Source | 783,369,000Source | 740,700,000Source | 760,000,000Source | 780,517,000Source | 719,316,000Source |
| Assets, CurrentUSD | 2,842,000,000Source | 3,055,620,000Source | 3,020,500,000Source | 2,811,100,000Source | 3,056,254,000Source | 2,942,100,000Source | 3,036,600,000Source | 3,060,936,000Source | 2,906,200,000Source | 3,030,300,000Source | 3,048,330,000Source | 3,157,976,000Source |
| Operating Lease, Right-of-Use AssetUSD | 180,300,000Source | 173,866,000Source | 154,000,000Source | 190,400,000Source | 181,473,000Source | 161,900,000Source | 153,200,000Source | 188,918,000Source | 170,000,000Source | 160,500,000Source | 194,730,000Source | 180,952,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | 102,700,000Source | 101,900,000Source | 94,850,000Source | 94,599,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,959,600,000Source | 3,115,613,000Source | 3,078,100,000Source | 3,085,400,000Source | 2,909,659,000Source | 2,938,700,000Source | 2,847,500,000Source | 3,558,759,000Source | 3,122,900,000Source | 2,794,800,000Source | 3,557,937,000Source | 3,886,414,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — | 0Source |
| Additional Paid in CapitalUSD | 461,900,000Source | 448,329,000Source | 502,900,000Source | 484,600,000Source | 474,729,000Source | 490,500,000Source | 475,700,000Source | 462,627,000Source | 476,000,000Source | 463,200,000Source | 449,075,000Source | 447,454,000Source |
| Retained Earnings (Accumulated Deficit)USD | 7,456,300,000Source | 8,132,231,000Source | 8,020,600,000Source | 7,798,200,000Source | 7,479,059,000Source | 7,649,200,000Source | 7,480,400,000Source | 9,644,545,000Source | 8,176,300,000Source | 7,416,400,000Source | 9,260,629,000Source | 9,898,203,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -166,800,000Source | -315,274,000Source | -271,300,000Source | -154,100,000Source | -451,362,000Source | -235,400,000Source | -409,800,000Source | -425,971,000Source | -189,100,000Source | -538,200,000Source | -336,038,000Source | -466,822,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,736,800,000Source | 7,487,900,000Source | 7,173,900,000Source | 7,128,700,000Source | 6,778,900,000Source | 6,851,300,000Source | 6,679,400,000Source | 9,051,300,000Source | 7,453,600,000Source | 6,569,300,000Source | 8,741,133,000Source | 9,615,252,000Source |
| Liabilities and EquityUSD | 9,696,400,000Source | 10,603,472,000Source | 10,252,000,000Source | 10,214,100,000Source | 9,688,446,000Source | 9,790,000,000Source | 9,526,900,000Source | 12,609,893,000Source | 10,576,500,000Source | 9,364,100,000Source | 12,299,070,000Source | 13,501,666,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 522,300,000Source | 497,943,000Source | 961,300,000Source | 548,900,000Source | 486,961,000Source | 917,000,000Source | 506,600,000Source | 466,154,000Source | 517,000,000Source | 467,800,000Source | 522,799,000Source | 568,708,000Source |
| Operating Lease, Liability, CurrentUSD | 36,800,000Source | 42,834,000Source | 33,600,000Source | 39,300,000Source | 41,513,000Source | 36,200,000Source | 41,300,000Source | 40,038,000Source | 36,100,000Source | 41,700,000Source | 40,379,000Source | 36,336,000Source |
| Accounts Payable, CurrentUSD | 128,800,000Source | 122,185,000Source | 143,500,000Source | 139,300,000Source | 126,693,000Source | 133,100,000Source | 137,900,000Source | 102,750,000Source | 129,000,000Source | 122,300,000Source | 144,625,000Source | 135,041,000Source |
| Operating Lease, Liability, NoncurrentUSD | 155,800,000Source | 143,919,000Source | 133,100,000Source | 164,800,000Source | 150,975,000Source | 138,600,000Source | 126,300,000Source | 159,814,000Source | 145,700,000Source | 131,400,000Source | 165,478,000Source | 153,597,000Source |
| Deferred Income Tax Liabilities, NetUSD | 872,600,000Source | 1,076,058,000Source | 982,200,000Source | 961,000,000Source | 878,462,000Source | 881,800,000Source | 840,800,000Source | 1,540,992,000Source | 1,059,400,000Source | 818,000,000Source | 1,475,495,000Source | 1,770,481,000Source |
| Other Liabilities, NoncurrentUSD | 207,500,000Source | 197,631,000Source | 198,500,000Source | 209,600,000Source | 193,537,000Source | 198,400,000Source | 173,100,000Source | 192,418,000Source | 199,100,000Source | 177,200,000Source | 195,113,000Source | 195,912,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 50,200,000Source | 48,900,000Source | 52,500,000Source | 54,400,000Source | 52,000,000Source | 56,300,000Source | 53,800,000Source | 55,100,000Source | 48,900,000Source | 47,800,000Source | 51,100,000Source | 52,211,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,014,400,000Source | 771,400,000Source | 1,433,000,000Source | 1,725,100,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | 1,201,700,000Source | 1,200,400,000Source | 1,199,100,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,201,400,000Source | 1,200,062,000Source | 803,000,000Source | 1,201,100,000Source | 1,199,724,000Source | 802,900,000Source | 1,200,700,000Source | 1,199,381,000Source | 1,201,700,000Source | 1,200,400,000Source | 1,199,100,000Source | — |
| Short-term InvestmentsUSD | 1,022,800,000Source | 1,212,081,000Source | 1,101,500,000Source | 1,004,500,000Source | 1,209,193,000Source | 1,057,500,000Source | 1,139,000,000Source | 1,212,394,000Source | 1,010,900,000Source | 1,176,400,000Source | 1,203,327,000Source | 1,356,457,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 40,900,000Source | 38,100,000Source | 165,400,000Source | 151,600,000Source | 145,900,000Source | 137,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 15,000,000Source | 15,300,000Source | 58,000,000Source | 62,300,000Source | 61,300,000Source | 60,900,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -30,800,000Source | -37,200,000Source | -19,600,000Source | -16,200,000Source | -11,400,000Source | 87,400,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 29,900,000Source | 17,900,000Source | -68,900,000Source | -8,500,000Source | 46,300,000Source | 158,800,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 170,500,000Source | -626,800,000Source | -322,600,000Source | -1,241,600,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 108,100,000Source | 129,900,000Source | 532,200,000Source | 455,200,000Source | 374,943,000Source | 194,447,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -93,200,000Source | 2,900,000Source | -189,700,000Source | -160,200,000Source | 20,208,000Source | -1,207,593,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,375,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 30,000,000Source | 34,400,000Source | 157,600,000Source | 165,600,000Source | 156,680,000Source | 112,782,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 3,000,000Source | 3,400,000Source | 14,936,000Source | 13,967,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 47,800,000Source | 101,900,000Source | 295,500,000Source | 203,600,000Source | 428,728,000Source | 215,679,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -44,000,000Source | -97,700,000Source | -283,200,000Source | -218,800,000Source | -425,647,000Source | 973,576,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 100,000Source | 100,000Source | 500,000Source | 400,000Source | 467,000Source | 510,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -23,200,000Source | 33,300,000Source | 42,400,000Source | 85,400,000Source | -30,175,000Source | -36,589,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 398,200,000Source | 412,200,000Source | 518,800,000Source | 371,700,000Source | 509,000,000Source | 523,100,000Source | 532,200,000Source | 489,800,000Source | 404,369,000Source | 434,544,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 11,000,000Source | 7,900,000Source | 61,600,000Source | 99,400,000Source | 129,593,000Source | 158,259,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 58,000,000Source | 62,300,000Source | 61,300,000Source | 60,900,000Source |
| Amortization of Intangible AssetsUSD | — | — | 7,300,000Source | 5,300,000Source | 6,000,000Source | 5,200,000Source | 5,900,000Source | 5,000,000Source | 23,800,000Source | 21,200,000Source | 23,800,000Source | 24,900,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | 900,400,000Source | -2,656,800,000Source | -1,252,251,000Source | -5,193,554,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | -1,300,000Source | -2,200,000Source | -1,300,000Source | -200,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 141,400,000Source | — | — | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | — | — | 40,000,000Source | 41,200,000Source | 46,500,000Source | 39,900,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | 6,000,000Source | 0Source | — | — | — | — | 6,000,000Source | 0Source | 0Source | 11,900,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | 1,800,000Source | 25,200,000Source | 15,100,000Source | -2,400,000Source | -8,400,000Source | 4,600,000Source | -12,400,000Source | -12,500,000Source | 6,800,000Source | 100,600,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 2,900,000Source | -1,600,000Source | 200,000Source | -1,100,000Source | 2,400,000Source | 2,700,000Source | 6,600,000Source | 3,900,000Source | 7,347,000Source | 205,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | 5,900,000Source | -14,400,000Source | 43,500,000Source | -20,700,000Source | 9,900,000Source | -19,900,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -2,500,000Source | -1,400,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,400,000Source |
| GoodwillUSD | — | — | 578,700,000Source | 415,100,000Source | 574,300,000Source | 581,600,000Source | 577,100,000Source | 414,600,000Source | 579,800,000Source | 410,500,000Source | 413,569,000Source | 406,488,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 172,800,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | -89,200,000Source | 208,400,000Source | 170,700,000Source | 96,200,000Source | -162,700,000Source | 19,400,000Source | 235,600,000Source | -498,300,000Source | -212,780,000Source | -1,076,738,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | -495,300,000Source | 792,900,000Source | 458,000,000Source | 334,400,000Source | -738,200,000Source | 31,800,000Source | 900,400,000Source | -2,656,800,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -341,900,000Source | 653,200,000Source | 371,400,000Source | 317,800,000Source | -527,100,000Source | 64,000,000Source | 759,900,000Source | -1,844,200,000Source | -637,324,000Source | -3,627,535,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 8,300,000Source | 17,900,000Source | 23,400,000Source | 16,200,000Source | 24,200,000Source | 37,200,000Source | 90,300,000Source | 90,300,000Source | 106,443,000Source | 44,574,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 226,100,000Source | 153,400,000Source | 669,300,000Source | 1,276,600,000Source | 689,041,000Source | 2,060,238,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 3,400,000Source | 4,300,000Source | — | — | — | -3,373,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 17,700,000Source | 19,500,000Source | 62,000,000Source | 199,300,000Source | 361,279,000Source | 357,813,000Source |
| Provision for Loan, Lease, and Other LossesUSD | — | — | — | — | — | — | — | — | 1,400,000Source | 0Source | 0Source | 7,500,000Source |
| Realized Investment Gains (Losses)USD | — | — | 1,000,000Source | 2,000,000Source | 300,000Source | 900,000Source | 2,500,000Source | 500,000Source | 1,000,000Source | 6,700,000Source | 700,000Source | 2,300,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 2,583,200,000Source | 2,566,500,000Source | 2,671,262,000Source | 2,802,249,000Source |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 653,000,000Source | 649,700,000Source | 651,000,000Source | 651,600,000Source | 592,100,000Source | 585,400,000Source | 2,583,200,000Source | 2,566,500,000Source | 2,671,300,000Source | 2,802,200,000Source |
| Cost of RevenueUSD | — | — | 309,600,000Source | 293,800,000Source | 305,200,000Source | 306,300,000Source | 282,700,000Source | 279,400,000Source | 1,243,300,000Source | 1,187,600,000Source | 1,244,316,000Source | 1,234,919,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 206,800,000Source | 200,400,000Source | 212,000,000Source | 207,700,000Source | 212,400,000Source | 208,800,000Source | 844,300,000Source | 814,000,000Source | 841,723,000Source | 827,825,000Source |
| Operating Income (Loss)USD | — | — | 65,300,000Source | 64,500,000Source | 72,600,000Source | 77,100,000Source | 34,100,000Source | 23,700,000Source | 47,200,000Source | 269,000,000Source | 337,796,000Source | 482,616,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 8,300,000Source | 17,900,000Source | 23,400,000Source | 16,200,000Source | 24,200,000Source | 37,200,000Source | 90,300,000Source | 90,300,000Source | 106,443,000Source | 44,574,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -431,100,000Source | 861,600,000Source | 542,100,000Source | 414,000,000Source | -689,800,000Source | 83,400,000Source | 995,500,000Source | -2,342,500,000Source | -850,104,000Source | -4,704,273,000Source |
| Income Tax Expense (Benefit)USD | — | — | -89,200,000Source | 208,400,000Source | 170,700,000Source | 96,200,000Source | -162,700,000Source | 19,400,000Source | 235,600,000Source | -498,300,000Source | -212,780,000Source | -1,076,738,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -341,900,000Source | 653,200,000Source | 371,400,000Source | 317,800,000Source | -527,100,000Source | 64,000,000Source | 759,900,000Source | -1,844,200,000Source | -637,324,000Source | -3,627,535,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -12.7Source | 23.37Source | 13.89Source | 11.67Source | -19.55Source | 2.29Source | 27.87Source | -65.36Source | -21.82Source | -121.79Source |
| Earnings Per Share, DilutedUSD per share | — | — | -12.7Source | 23.34Source | 13.85Source | 11.67Source | -19.55Source | 2.29Source | 27.85Source | — | -21.82Source | -121.79Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,923,000Source | 27,949,000Source | 26,746,000Source | 27,226,000Source | 26,958,000Source | 27,941,000Source | 27,263,000Source | 28,214,000Source | 29,209,000Source | 29,785,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,923,000Source | 27,985,000Source | 26,814,000Source | 27,228,000Source | 26,958,000Source | 27,955,000Source | 27,281,000Source | 28,214,000Source | 29,209,000Source | 29,785,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 7,300,000Source | 5,300,000Source | 6,000,000Source | 5,200,000Source | 5,900,000Source | 5,000,000Source | 23,800,000Source | 21,200,000Source | 23,800,000Source | 24,900,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 63,000,000Source | 123,500,000Source | 103,200,000Source | 157,000,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | 900,400,000Source | -2,656,800,000Source | -1,252,251,000Source | -5,193,554,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | -1,300,000Source | -2,200,000Source | -1,300,000Source | -200,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | 1,800,000Source | 25,200,000Source | 15,100,000Source | -2,400,000Source | -8,400,000Source | 4,600,000Source | -12,400,000Source | -12,500,000Source | 6,800,000Source | 100,600,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 2,900,000Source | -1,600,000Source | 200,000Source | -1,100,000Source | 2,400,000Source | 2,700,000Source | 6,600,000Source | 3,900,000Source | 7,347,000Source | 205,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | 5,900,000Source | -14,400,000Source | 43,500,000Source | -20,700,000Source | 9,900,000Source | -19,900,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Gross ProfitUSD | — | — | 343,400,000Source | 355,900,000Source | 345,800,000Source | 345,300,000Source | 309,400,000Source | 306,000,000Source | 1,339,900,000Source | 1,378,900,000Source | 1,426,946,000Source | 1,567,330,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 801,400,000Source | -1,117,000,000Source | -31,000,000Source | -2,403,400,000Source |
| Interest ExpenseUSD | — | — | 12,300,000Source | 12,100,000Source | 12,100,000Source | 12,600,000Source | 12,300,000Source | 12,000,000Source | 49,000,000Source | 48,900,000Source | 49,439,000Source | 38,114,000Source |
| Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost ComponentUSD | — | — | — | — | — | — | — | — | -600,000Source | -500,000Source | -400,000Source | -300,000Source |
| Realized Investment Gains (Losses)USD | — | — | 1,000,000Source | 2,000,000Source | 300,000Source | 900,000Source | 2,500,000Source | 500,000Source | 1,000,000Source | 6,700,000Source | 700,000Source | 2,300,000Source |
| Research and Development ExpenseUSD | — | — | 71,300,000Source | 91,000,000Source | 61,200,000Source | 60,500,000Source | 62,900,000Source | 73,500,000Source | 275,600,000Source | 295,900,000Source | 247,427,000Source | 256,889,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | 2,583,200,000Source | 2,566,500,000Source | 2,671,262,000Source | 2,802,249,000Source |
Filing attachments
bio-8k1142026xex991.htm · 8-K · 2026-11-04
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2026 Financial Results HERCULES, Calif. - November 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral…
Read attachment ↗bio-8k842026xex991.htm · 8-K · 2026-08-04
EX-99.1 2 bio-8k842026xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2026 Financial Results HERCULES, Calif. - August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat yea…
Read attachment ↗bio-8k4302026xex991.htm · 8-K · 2026-04-30
EX-99.1 2 bio-8k4302026xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2026 Financial Results HERCULES, Calif. - April 30, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our reso…
Read attachment ↗ex992-bioxrad1q26earning.htm · 8-K · 2026-04-30
EX-99.2 3 ex992-bioxrad1q26earning.htm EX-99.2 ex992-bioxrad1q26earning Supplemental Earnings Results Presentation April 30, 2026 First Quarter 2026 Financial Results 2 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future financial projections, o…
Read attachment ↗bio-8k2122026xex991.htm · 8-K · 2026-02-12
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results HERCULES, Calif. - February 12, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued press…
Read attachment ↗bio-8k10292025xex991.htm · 8-K · 2025-10-29
EX-99.1 2 bio-8k10292025xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2025 Financial Results HERCULES, Calif. - October 29, 2025 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across…
Read attachment ↗